Cambrex Corporation  

(Public, NYSE:CBM)   Watch this stock  
Find more results for CBM
-0.48 (-0.96%)
After Hours: 49.05 0.00 (0.00%)
Nov 22, 4:46PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 48.70 - 50.40
52 week 42.55 - 62.95
Open 49.55
Vol / Avg. 323,105.00/510,058.00
Mkt cap 1.61B
P/E 16.10
Div/yield     -
EPS 3.05
Shares 32.77M
Beta 2.25
Inst. own 109%
Feb 1, 2018
Q4 2017 Cambrex Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 8, 2017
Cambrex Corp at Stephens Fall Investment Conference
Nov 7, 2017
Q3 2017 Cambrex Corp Earnings Release
Nov 7, 2017
Q3 2017 Cambrex Corp Earnings Call - Webcast
Sep 25, 2017
Cambrex Corp at Cantor Fitzgerald Global Healthcare Conference
Sep 7, 2017
Cambrex Corp at Robert W Baird Gobal Healthcare Conference
Sep 6, 2017
Cambrex Corp at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 15.34% 17.80%
Operating margin 22.29% 26.16%
EBITD margin - 31.42%
Return on average assets 10.11% 15.63%
Return on average equity 14.31% 24.38%
Employees 1,295 -
CDP Score - -


1 Meadowlands Plz
E RUTHERFORD, NJ 07073-2150
United States - Map
+1-201-8043000 (Phone)
+1-201-8049852 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Officers and directors

Steven Mark Klosk President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Tom George Vadaketh Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Shawn P. Cavanagh Chief Operating Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gregory P. Sargen Executive Vice President, Corporate Development and Strategy
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Samantha M. Hanley Vice President, General Counsel,Corporate Secretary
Age: 39
Bio & Compensation  - Reuters
James G. Farrell Vice President and Corporate Controller
Age: 50
Bio & Compensation  - Reuters
Shlomo Yanai Non-Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Gregory B. Brown M.D. Director
Age: 64
Bio & Compensation  - Reuters
Rosina B. Dixon M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Claes Glassell Independent Director
Age: 65
Bio & Compensation  - Reuters